Impacts of alcohol use & obesity on outcome of ETV therapy

肝胆速递

Clin Mol Hepatol. 2012 Jun;18(2):195-202. Epub 2012 Jun 26.
Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection.
Chung WG, Kim HJ, Choe YG, Seok HS, Chon CW, Cho YK, Kim BI, Koh YY.
Source

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
BACKGROUND/AIMS:

The aim of this study was to analyze the clinical impacts of obesity and hazardous alcohol use on the outcome of entecavir (ETV) therapy in chronic hepatitis B (CHB) patients.
METHODS:

The medical records of 88 treatment-naïve patients who were diagnosed with CHB and received ETV between March 2007 and September 2009 were analyzed retrospectively. Body mass index (BMI) values and Alcohol Use Disorders Identification Test (AUDIT) scores were obtained at 6 months after the initiation of ETV (0.5 mg daily) treatment.
RESULTS:

A BMI of 25 kg/m(2) or more was recognized as an indicator of obesity, and a total AUDIT score of 8 or more was recognized as an indicator of hazardous alcohol use. Of the cohort, 24 patients (27.3%) were obese and 17 (19.3%) were hazardous alcohol users. The rate of seroconversion, alanine aminotransferase (ALT) normalization, and hepatitis B virus (HBV)-DNA negativity (<300 copies/mL) at 3, 6, and 12 months of treatment did not differ significantly between the normal-BMI and high-BMI groups. Moreover, the rate of seroconversion and HBV-DNA negativity at 3, 6, and 12 months of treatment did not differ significantly between the nonhazardous and hazardous alcohol users. However, the frequency of ALT normalization at 12 months was significantly lower among hazardous alcohol users (91.5% vs. 70.6%; P=0.033).
CONCLUSIONS:

Obesity and hazardous alcohol drinking have no significant impact on the outcome of ETV treatment. However, the ALT normalization rate at 12 months after initiation of ETV treatment was significantly lower among the hazardous alcohol users.

肝胆速递

临床Mol.肝脏病杂志。 2012 18（2）:195-202。 EPUB 2012年6月26日。
有害使用酒精和肥胖的结果，恩替卡韦治疗慢性B型肝炎感染的治疗初治患者的临床影响。
，金，锡，金HJ，崔涌WG YG HS，春CW，赵YK BI，苏梅YY。
源

胃肠病学和肝病科，内科，江北三星医院成均馆大学医学院，首尔，韩国。
抽象
背景/目的：

本研究的目的是分析的结果，恩替卡韦（ETV）治疗慢性乙型肝炎（CHB）患者的临床肥胖和有害使用酒精的影响。
方法：

谁被诊断为慢性乙型肝炎患者和接受ETV 2007年3月至2009年9月88治疗初治患者的医疗记录进行了回顾性分析。身体质量指数（BMI）值与酒精使用障碍鉴别试验（AUDIT）分数在6个月后开始ETV（每天0.5毫克）治疗。
结果：

体重指数为25公斤/米（2）或以上被认定为肥胖的指标，被认定为有害使用酒精的指标和8个或更多的得分，总审计。的队列，24例（27.3％），肥胖和危险的饮酒者17人（19.3％）。 3率血清学转换，丙氨酸氨基转移酶（ALT）正常化，以及B型肝炎病毒（HBV）DNA转阴（<300拷贝/毫升），6个月和12个月的治疗没有显着差异之间的正常体重指数和高显着BMI组。此外，血清学转换和HBV-DNA消极3，6个月和12个月的治疗率并没有差异之间的非危险和有害饮酒者显着。然而，在12个月ALT正常化的频率显着较低，有害饮酒者（91.5％比70.6％，P = 0.033）。
结论：

肥胖和有害饮酒ETV治疗的结果并没有显着的影响。然而，在12个月后开始ETV治疗的ALT复常率显着较低，有害酒精的用户。